Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus.

No Thumbnail Available
Authors
Taylor, E. L.
Armstrong, K. R.
Perrett, D.
Hattersley, Andrew T.
Winyard, Paul G.
Journal
Oxidative medicine and cellular longevity
Type
Journal Article
Research Support, Non-U.S. Gov't
Publisher
Hindawi
Rights
Archived with thanks to Oxidative medicine and cellular longevity
Advanced oxidation protein products (AOPP) are reportedly elevated in the plasma of patients with a number of diseases, including diabetes mellitus, that involve oxidative stress. However, the accurate measurement of AOPP in human plasma is hampered by the formation of a precipitate following the addition of potassium iodide and glacial acetic acid according to the published assay procedure. Here we describe a modification of the AOPP assay which eliminates interference by precipitation and provides a robust, reliable, and reproducible protocol for the measurement of iodide oxidising capacity in plasma samples (intra-assay CV 1.7-5.3%, interassay CV 5.3-10.5%). The improved method revealed a significant association of AOPP levels with age (p < 0.05) and hypertension (p = 0.01) in EDTA-anticoagulated plasma samples from 52 patients with diabetes and 38 nondiabetic control subjects, suggesting a possible link between plasma oxidising capacity and endothelial and/or vascular dysfunction. There was no significant difference between AOPP concentrations in diabetic (74.8 ± 7.2 μM chloramine T equivalents) and nondiabetic (75.5 ± 7.0 μM chloramine T equivalents) individuals.
Citation
Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus. 2015, 2015:496271 Oxid Med Cell Longev
Note
This article is freely available from the publisher's site - click on the 'Additional Link' above to access the full text.